BR112023027321A2 - Uso de um polipeptídeo, composição que compreende trirreceptor ggg, e dispositivo - Google Patents

Uso de um polipeptídeo, composição que compreende trirreceptor ggg, e dispositivo

Info

Publication number
BR112023027321A2
BR112023027321A2 BR112023027321A BR112023027321A BR112023027321A2 BR 112023027321 A2 BR112023027321 A2 BR 112023027321A2 BR 112023027321 A BR112023027321 A BR 112023027321A BR 112023027321 A BR112023027321 A BR 112023027321A BR 112023027321 A2 BR112023027321 A2 BR 112023027321A2
Authority
BR
Brazil
Prior art keywords
trireceptor
ggg
polypeptide
composition
glucagon
Prior art date
Application number
BR112023027321A
Other languages
English (en)
Portuguese (pt)
Inventor
Shweta Urva
Tamer Coskun
Zvonko Milicevic
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112023027321A2 publication Critical patent/BR112023027321A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112023027321A 2021-06-23 2022-06-22 Uso de um polipeptídeo, composição que compreende trirreceptor ggg, e dispositivo BR112023027321A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163213956P 2021-06-23 2021-06-23
PCT/US2022/034437 WO2022271767A1 (en) 2021-06-23 2022-06-22 An incretin analog for use in glycemic control and weight management

Publications (1)

Publication Number Publication Date
BR112023027321A2 true BR112023027321A2 (pt) 2024-03-12

Family

ID=82608370

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023027321A BR112023027321A2 (pt) 2021-06-23 2022-06-22 Uso de um polipeptídeo, composição que compreende trirreceptor ggg, e dispositivo

Country Status (11)

Country Link
US (3) US12496329B2 (https=)
EP (1) EP4358994A1 (https=)
JP (1) JP2024524180A (https=)
KR (1) KR20240024936A (https=)
CN (1) CN117915939A (https=)
AU (2) AU2022298662B2 (https=)
BR (1) BR112023027321A2 (https=)
CA (1) CA3223313A1 (https=)
IL (1) IL309604A (https=)
MX (3) MX2024000213A (https=)
WO (1) WO2022271767A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102812908B1 (ko) * 2019-08-19 2025-05-28 일라이 릴리 앤드 캄파니 인크레틴 유사체의 제조 방법
CN117320740A (zh) * 2021-02-17 2023-12-29 伊莱利利公司 Gip/glp1双重激动剂治疗方法
WO2026037397A1 (zh) * 2024-08-16 2026-02-19 江苏恒瑞医药股份有限公司 Glp-1类似物的医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2548275T3 (es) 2010-03-01 2015-10-15 Eli Lilly And Company Dispositivo de inyección automático con mecanismo de retardo que incluye un elemento de empuje de funcionamiento doble
KR102589234B1 (ko) 2017-11-21 2023-10-16 일라이 릴리 앤드 캄파니 둘라글루티드를 함유하는 조성물 및 사용 방법
AR113486A1 (es) 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
TWI767095B (zh) 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
TW202140058A (zh) 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途

Also Published As

Publication number Publication date
JP2024524180A (ja) 2024-07-05
US20260091088A1 (en) 2026-04-02
US20240325498A1 (en) 2024-10-03
EP4358994A1 (en) 2024-05-01
KR20240024936A (ko) 2024-02-26
AU2022298662A1 (en) 2024-01-18
CN117915939A (zh) 2024-04-19
IL309604A (en) 2024-02-01
AU2025220848A1 (en) 2025-09-11
US20260091087A1 (en) 2026-04-02
MX2024000213A (es) 2024-04-16
MX2025012714A (es) 2025-11-03
AU2022298662B2 (en) 2025-06-05
US12496329B2 (en) 2025-12-16
MX2025012713A (es) 2025-11-03
WO2022271767A1 (en) 2022-12-29
CA3223313A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
BR112023027321A2 (pt) Uso de um polipeptídeo, composição que compreende trirreceptor ggg, e dispositivo
CL2008003243A1 (es) Compuesto que exhibe actividad antagonista del glucagon y actividad agonista del peptido-1 tipo glucagon (glp); composicion farmaceutica y kit que lo comprende; y su uso para tratar hiperglucemia.
BR112022009396A2 (pt) Análogos de incretina e usos dos mesmos
CL2020002574A1 (es) Análogos novedosos de glp-1
ECSP19046893A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
CL2008003222A1 (es) Peptidos con actividad antagonista de glucagon y composicion farmaceutica que los comprende, utiles para el tratamiento de la hiperglicemia, para suprimir el apetito, reducir el aumento de peso y para tratar el desgaste catabolico.
BR112023003668A2 (pt) Agonistas duplos de glp-1/gip
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
DOP2017000102A (es) Coagonistas de los receptores de glucagón y de glp-1
CL2012002635A1 (es) Péptido que presenta actividad para el receptor del péptido insulinotrópico dependiente de glucosa (gip-r) y para el receptor del péptido-1 similar al glucagón (glp-1-r) y son selectivos sobre el receptor del glucagón (gluc-r); formulación farmacéutica que lo comprende; y su uso para el tratamiento de diabetes mellitus y para la pérdida de peso.
CO2025001430A2 (es) Agonista dual de glp-1/gip, método de preparación y uso del mismo
MX2020011007A (es) Derivado de péptido-1 (glp-1) similar al glucagón acilado.
CO2023012373A2 (es) Composiciones que contienen análogos de incretina y usos de estas
CL2024000647A1 (es) Régimen de dosificación
AR128464A1 (es) Péptidos agonistas duales glp-1 y glucagón con estabilidad biológica mejorada
MX2023001601A (es) Composicion farmaceutica hipotensora que comprende un activador triple que tiene actividad para todos los receptores de glucagon, glp-1, y gip.
JOP20250233A1 (ar) مُنشِّط ثلاثي جديد لمستقبلاتglp-1/gip/ جلوكاجون، وتركيب صيدلاني للوقاية من أو علاج السمنة الذي يحتوي عليه
CL2024000429A1 (es) Contra enfermedades inflamatorias intestinales que involucra la disrupción del ensamblaje de heterómeros ccr9:drd5
PE20251599A1 (es) Metodos para el tratamiento de la obesidad
MX2024014840A (es) Métodos de uso de un coagonista de gcg/glp1 para terapia
EA202191184A1 (ru) Фармацевтическая композиция, содержащая аналог glp-1

Legal Events

Date Code Title Description
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025000167-8 PROTOCOLO 870250000887 EM 06/01/2025 15:43.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]